Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells.
Lipopolysaccharide-stimulated murine B lymphocytes were incubated with the pharmacologic drug lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase at concentrations ranging from 10(-5)-10(-8) M. After 48 hr, treatment with 10(-5)M lovastatin inhibited [3H]thymidine incorporation 55%. Flow cytometric analysis indicated that the fraction of B cells in S phase was reduced from 26.7% +/- 5.44% to 11.6% +/- 2.9% when cells were incubated with 10(-5)M lovastatin. In addition, a large peak appeared to the left of the G1 peak that was indicative of apoptosis in cells treated with 10(-5)M lovastatin. At 96 hr, the number of plaque-forming B cells was decreased 50% in the presence of lovastatin. Together these results suggest that high concentrations of lovastatin can inhibit B cell proliferation and differentiation of murine B lymphocytes in lipopolysaccharide-activated B cells, perhaps through induction of programmed cell death.